Fredun Pharmaceuticals Hits New 52-Week High of Rs. 1519.95

Fredun Pharmaceuticals has reached a significant milestone by hitting a new 52-week high of Rs. 1519.95 on October 14, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, particularly as it has demonstrated a remarkable annual growth rate in net sales of 38.16% and an operating profit growth of 56.18%.
Despite today's performance showing a slight underperformance against its sector by 0.49%, Fredun Pharmaceuticals has consistently traded above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Over the past year, the stock has generated an impressive return of 89.75%, significantly outperforming the Sensex, which has only seen a 0.41% increase.

The company has also reported positive results for the last five consecutive quarters, with net sales for the latest quarter reaching Rs. 119.85 crore, reflecting a growth of 52.06%. With a return on capital employed (ROCE) of 16.8 and a PEG ratio of 0.9, Fredun Pharmaceuticals continues to showcase its strong market position and financial health.